Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis

J Carlo Hojilla, David Vlahov, David V Glidden, K Rivet Amico, Megha Mehrotra, Robert Hance, Robert M Grant, Adam W Carrico, J Carlo Hojilla, David Vlahov, David V Glidden, K Rivet Amico, Megha Mehrotra, Robert Hance, Robert M Grant, Adam W Carrico

Abstract

Introduction: Stimulant and heavy alcohol use are prevalent and associated with elevated risk for HIV seroconversion among men who have sex with men (MSM) and transgender women. In addition, each can pose difficulties for antiretroviral adherence among people living with HIV. Scant research has examined the associations of stimulant and heavy alcohol use with adherence to daily oral pre-exposure prophylaxis (PrEP) among MSM and transgender women. To address this gap in the literature, we evaluated the hypothesis that stimulant use and binge drinking are prospectively associated with sub-optimal PrEP adherence.

Methods: We analysed data from participants in a nested case-cohort in the iPrEx open label extension. Stimulant use (i.e. powder cocaine, crack-cocaine, cocaine paste, methamphetamine, cathinone) and binge drinking (i.e. ≥5 drinks in a single day) in the last 30 days were assessed. Baseline urine was tested for stimulants using immunoassays to reduce misclassification. Sub-optimal adherence was defined as tenofovir drug concentrations in dried blood spots less than 700 fmol per punch, indicative of less than four doses per week. We tested the prospective association of stimulant use and binge drinking with sub-optimal adherence at the 4-week follow-up visit.

Results and discussion: Data from 330 participants were analysed. The majority of the participants were MSM (89%) with a median age at baseline of 29 years (interquartile range 24 to 39). Approximately 16% (52/330) used stimulants and 22% (72/330) reported binge drinking in the last 30 days. Stimulant users had fivefold greater odds of sub-optimal PrEP adherence compared to non-users in adjusted analysis (adjusted odds ratio [aOR] 5.04; [95% CI 1.35 to 18.78]). Self-reported binge drinking was not significantly associated with sub-optimal adherence after adjusting for stimulant use and baseline confounders (aOR 1.16 [0.49 to 2.73]). Depressive symptoms, being transgender, and number of sex partners were also not significantly associated with sub-optimal PrEP adherence (p > 0.05).

Conclusions: Stimulant use is a risk factor for sub-optimal PrEP adherence in the month following PrEP initiation. Comprehensive prevention approaches that reduce stimulant use may optimize PrEP adherence. Creating adherence plans that specifically address PrEP dosing in the context of ongoing stimulant use should also be considered.

Keywords: adherence; binge drinking; drug use; men who have sex with men; pre-exposure prophylaxis; stimulant use; transgender persons.

© 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society.

References

    1. UNAIDS . Prevention gap report. Geneva, Switzerland; 2016. Available from: [cited 2017 Aug 12]
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
    1. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre‐exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.
    1. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal‐ and community‐based sexualhealth services. JAMA Intern Med. 2016;176(1):11–75.
    1. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.
    1. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre‐exposure prophylaxis to prevent the acquisition of HIV‐1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open‐label randomised trial. Lancet. 2016;387(10013):53–60.
    1. Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on‐demand pre‐exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.
    1. Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr. 2015;68(4):439–48.
    1. Sevelius JM, Keatley J, Calma N, Arnold E. “I am not a man”: trans‐specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016;11(7–8):1060–75.
    1. Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. HIV pre‐exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–9.
    1. Blashill AJ, Ehlinger PP, Mayer KH, Safren SA. Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach. Clin Infect Dis. 2015;60(suppl 3):S187–90.
    1. Carrico AW, Riley ED, Johnson MO, Charlebois ED, Neilands TB, Remien RH, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. J Acquir Immune Defic Syndr. 2011;56(2):146–50.
    1. Plankey MW, Ostrow DG, Stall R, Cox C, Li X, Peck JA, et al. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Int AIDS Soc. 2007;45(1):85–92.
    1. Kirby T, Thornber-Dunwell M. High‐risk drug practices tighten grip on London gay scene. Lancet. 2013;381(9861):101–2.
    1. Sewell J, Miltz A, Lampe FC, Cambiano V, Speakman A, Phillips AN, et al. Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV‐negative men who have sex with men attending sexual health clinics. Int J Drug Policy. 2017;43:33–43.
    1. Ostrow DG, Plankey MW, Cox C, Li X, Shoptaw S, Jacobson LP, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr. 2009;51(3):349–55.
    1. Centers for Disease Control and Prevention . HIV infection risk, preventing, and testing behaviors among men who have sex with men - National HIV behavioral surveillance, 20 U.S. cities, 2014. [Internet]. Vol. 15. 2016. Available from: [cited 2018 Feb 18]
    1. Flentje A, Heck NC, Sorensen JL. Characteristics of transgender individuals entering substance abuse treatment. Addict Behav. 2014;39(5):969–75.
    1. Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2008;12(1):1–17.
    1. Reback CJ, Fletcher JB. HIV prevalence, substance use, and sexual risk behaviors among transgender women recruited through outreach. AIDS Behav. 2014;18(7):1359–67.
    1. Prentice RL. A case‐cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986;73(1):1–11.
    1. Radloff LS. The CES‐D Scale. Appl Psychol Meas. 1977;1(3):385–401.
    1. Glidden DV, Buchbinder SP, Anderson PL, McMahan V, Amico KR, Liu AY, et al. PrEP engagement for HIV prevention: Results from the iPrEx Open Label Extension. In: Conference on Retroviruses and Opportunistic Infections; 2015 Feb 23-26. Boston, USA. Available from:
    1. Weng H-Y, Hsueh Y-H, Messam LLM, Hertz-Picciotto I. Methods of covariate selection: directed acyclic graphs and the change‐in‐estimate procedure. Am J Epidemiol. 2009;169(10):1182–90.
    1. Meyer IH, Dietrich J, Schwartz S. Lifetime prevalence of mental disorders and suicide attempts in diverse lesbian, gay, and bisexual populations. Am J Public Health. 2008;98(6):1004–6.
    1. Defechereux PA, Mehrotra M, Liu AY, McMahan VM, Glidden DV, Mayer KH, et al. Depression and oral FTC/TDF pre‐exposure prophylaxis (PrEP) among men and transgender women who have sex with men (MSM/TGW). AIDS Behav. 2016;20(7):1478–88.
    1. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta‐analysis. J Acquir Immune Defic Synd. 2011;58(2):181–7.
    1. Mehrotra ML, Glidden DV, McMahan V, Amico KR, Hosek S, Defechereux P, et al. The effect of depressive symptoms on adherence to daily oral PrEP in men who have sex with men and transgender women: a marginal structural model analysis of the iPrEx OLE study. AIDS Behav. 2016;20(7):1527–34.
    1. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, et al. Drug use and medication adherence among HIV‐1 infected individuals. AIDS Behav. 2007;11(2):185–94.
    1. Marquez C, Mitchell SJ, Hare CB, John M, Klausner JD. Methamphetamine use, sexual activity, patient‐provider communication, and medication adherence among HIV‐infected patients in care, San Francisco 2004‐2006. AIDS Care. 2009;21(5):575–82.
    1. Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–3.
    1. Liu A, Cohen S, Follansbee S, Cohan D, Weber S, Sachdev D, et al. Early experiences implementing pre‐exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014;11(3):e1001613.
    1. Marcus JL, Hurley LB, Hare CB, Nguyen DP, Phengrasamy T, Silverberg MJ, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Synd. 2016;73(5):540–6.
    1. Chan PA, Mena L, Patel R, Oldenburg CE, Beauchamps L, Perez-Brumer AG, et al. Retention in care outcomes for HIV pre‐exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc. 2016;19(1):20903.
    1. Hojilla JC, Vlahov D, Crouch PC, Dawson-Rose C, Freeborn K, Carrico A. HIV pre‐exposure prophylaxis (PrEP) uptake and retention among men who have sex with men in a community‐based sexual health clinic. AIDS Behav. 2017;31(3):731.
    1. Coleman R, Prins M. Options for affordable pre‐exposure prophylaxis (PrEP) in national HIV prevention programmes in Europe. Euro Surveill. 2017;22(42):2179.
    1. Mayer KH, Chan PA, R Patel R, Flash CA, Krakower DS. Evolving models and ongoing challenges for HIV preexposure prophylaxis implementation in the United States. J Acquir Immune Defic Synd 2018;77(2):119–27.
    1. Cowan FM, Delany-Moretlwe S, Sanders EJ, Mugo NR, Guedou FA, Alary M, et al. PrEP implementation research in Africa: what is new? J Int AIDS Soc. 2016;19 7 Suppl 6: 21101.
    1. Buchbinder SP, Glidden DV, Liu AY, McMahan V, Guanira JV, Mayer KH, et al. HIV pre‐exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis. 2014;14(6):468–75.
    1. Shoptaw S, Reback CJ. Methamphetamine use and infectious disease‐related behaviors in men who have sex with men: implications for interventions. Addiction. 2007;102(Suppl 1):130–5.
    1. Carrico AW, Zepf R, Meanley S, Batchelder A, Stall R. Critical review: when the party is over: a systematic review of behavioral interventions for substance‐using men who have sex with men. J Acquir Immune Defic Synd. 2016;73(3):299–306.
    1. National Institute of Alcohol Abuse and Alcoholism . NIAAA council approves definition of binge drinking. 2004. Available from: [cited 2018 Feb 18]
    1. Hojilla JC, Koester KA, Cohen SE, Buchbinder S, Ladzekpo D, Matheson T, et al. Sexual behavior, risk compensation, and HIV prevention strategies among participants in the San Francisco PrEP Demonstration Project: a qualitative analysis of counseling notes. AIDS Behav. 2015;20:1–9.

Source: PubMed

Предстоящие клинические испытания

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться